Compare · ASLE vs EW
ASLE vs EW
Side-by-side comparison of AerSale Corporation (ASLE) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- ASLE operates in Consumer Discretionary, while EW operates in Health Care - the two are in different parts of the market.
- EW is the larger of the two at $50.41B, about 168.3x ASLE ($299.6M).
- Over the past year, ASLE is up 4.6% and EW is up 13.4% - EW leads by 8.8 points.
- ASLE has been more active in the news (8 items in the past 4 weeks vs 7 for EW).
- EW has more recent analyst coverage (25 ratings vs 5 for ASLE).
- Company
- AerSale Corporation
- Edwards Lifesciences Corporation
- Price
- $6.24-1.66%
- $86.01-1.71%
- Market cap
- $299.6M
- $50.41B
- 1M return
- -4.61%
- +11.46%
- 1Y return
- +4.63%
- +13.42%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 8
- 7
- Recent ratings
- 5
- 25
AerSale Corporation
AerSale Corporation provides aftermarket commercial aircraft, engines, and its parts to passenger and cargo airlines, leasing companies, original equipment manufacturers, and government and defense contractors, as well as maintenance, repair, and overhaul (MRO) service providers worldwide. It operates in two segments, Asset Management Solutions and Technical Operations (TechOps). The Asset Management Solutions segment engages in the sale and lease of aircraft, engines, and airframes, as well as disassembly of these assets for component parts. The TechOps segment provides internal and third-party aviation services, including internally developed engineered solutions, heavy aircraft maintenance and modification, and component MRO, as well as storage and disassembly services. This segment also provides aircraft modifications, cargo/tanker conversions of aircraft, and aircraft storage; and MRO services for landing gear, thrust reversers, hydraulic systems, and other aircraft components. The company was founded in 2008 and is headquartered in Coral Gables, Florida.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest ASLE
- Director Nichols Robert B. was granted 19,623 shares (SEC Form 4)
- Director Mullins Thomas Wiese was granted 19,623 shares, increasing direct ownership by 73% to 46,424 units (SEC Form 4)
- Director Mitchell Thomas Duncan was granted 19,623 shares, increasing direct ownership by 81% to 43,880 units (SEC Form 4)
- Director Levy Andrew C was granted 19,623 shares, increasing direct ownership by 32% to 80,528 units (SEC Form 4)
- Director Fedder Judith Ann was granted 19,623 shares, increasing direct ownership by 32% to 81,798 units (SEC Form 4)
- Director Dibattiste Carol was granted 19,623 shares, increasing direct ownership by 81% to 43,880 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by AerSale Corporation
- AerSale Announces Participation at the 2026 Jefferies Aftermarket MRO Virtual Summit
- SEC Form 10-Q filed by AerSale Corporation
- AerSale Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest EW
- SEC Form 3 filed by new insider Mistras Theodora
- SVP, Corporate Controller Dahl Andrew M. sold $48,853 worth of shares (568 units at $86.08), decreasing direct ownership by 4% to 15,334 units (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr sold $2,000,193 worth of shares (23,145 units at $86.42) (SEC Form 4)
- SEC Form SD filed by Edwards Lifesciences Corporation
- CVP, TMTT & Surgical Chopra Daveen sold $126,905 worth of shares (1,500 units at $84.60), decreasing direct ownership by 3% to 44,324 units (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 620 shares at a strike of $72.68 and sold $50,307 worth of shares (620 units at $81.14) as part of a pre-agreed trading plan (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr sold $1,472,678 worth of shares (17,968 units at $81.96), decreasing direct ownership by 30% to 22,798 units (SEC Form 4)
- CEO Zovighian Bernard J converted options into 47,207 shares, covered exercise/tax liability with 26,198 shares, gifted 26,640 shares, received a gift of 26,640 shares and sold $2,833,013 worth of shares (36,351 units at $77.93) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 99,165 units (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr converted options into 13,457 shares and covered exercise/tax liability with 7,469 shares, increasing direct ownership by 22% to 32,766 units (SEC Form 4)
- CVP, TMTT & Surgical Chopra Daveen converted options into 13,583 shares and covered exercise/tax liability with 7,538 shares, increasing direct ownership by 15% to 45,824 units (SEC Form 4)